Opthea Limited
OTC: CKDXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeremy Max Levin Ba Zoology Dphil Mb Bchir
- Employees
- 33
- Headquarters
- South Yarra, Australia
- IPO year
- 2011
- Market cap
- $13.7M
- Website
- https://opthea.com
Loading CKDXF…
Loading profile data…Frequently asked questions about CKDXF
What does Opthea Limited (CKDXF) do?
Operating primarily out of Australia, Opthea Limited is a clinical-stage biopharmaceutical firm dedicated to developing and marketing treatments for ophthalmic conditions. Its therapeutic pipeline leverages a robust intellectual property portfolio centered on Vascular Endothelial Growth Factors (VEGF) such as VEGF-C and VEGF-D, along with VEGF R...
Where does CKDXF trade?
Opthea Limited (CKDXF) trades on the Other OTC.
What sector is CKDXF in?
Opthea Limited (CKDXF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Opthea Limited?
Jeremy Max Levin Ba Zoology Dphil Mb Bchir is the chief executive officer of Opthea Limited (CKDXF).
Where is Opthea Limited headquartered?
Opthea Limited is headquartered in Australia.
Does CKDXF pay a dividend?
Opthea Limited (CKDXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CKDXF go public?
Opthea Limited (CKDXF) completed its initial public offering in 2011.